Evidence map›Paper›PMID 37039381›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2023

Notch signaling inactivation by small molecule γ-secretase inhibitors restores the multiciliated cell population in the airway epithelium.

Eszter K Vladar, Koshi Kunimoto, Laura S Rojas-Hernandez, Jacquelyn M Spano, Zachary M Sellers, Nam Soo Joo, Riley A Cooney, Jeffrey D Axelrod, Carlos E Milla

Open access · hybridAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  13. Article
  14. Examining the contribution of Notch signaling to lung disease development.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  15. The lysogenic filamentousPNAS nexus · 2024
    Article
  16. Article
  17. Emerging cell and molecular targets for treating mucus hypersecretion in asthma.Allergology international : official journal of the Japanese Society of Allergology · 2024
    Review
  18. NOTCH3 and Pulmonary Arterial Hypertension.International journal of molecular sciences · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eszter K VladarDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States.ORCID 0000-0002-4160-8894
Koshi KunimotoDepartment of Pathology, Stanford University School of Medicine, Stanford, California, United States.
Laura S Rojas-HernandezCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, California, United States.ORCID 0000-0002-0244-8912
Jacquelyn M SpanoCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, California, United States.
Zachary M SellersDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States.ORCID 0000-0001-5352-7760
Nam Soo JooCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, California, United States.
Riley A CooneyDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States.ORCID 0000-0003-0921-6943
Jeffrey D AxelrodDepartment of Pathology, Stanford University School of Medicine, Stanford, California, United States.ORCID 0000-0001-6094-7392
Carlos E MillaCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, California, United States.ORCID 0000-0001-5515-3053
Stanford University · USUniversity of Colorado Denver · US

Funding

Planar cell polarity mechanisms and systems architectureR35GM131914 · NIGMS · STANFORD UNIVERSITY · PI Jeffrey D. Axelrod · 2019 to 2026
$7.4M
6 · The paper itself

Abstract

Multiciliated cell loss is a hallmark of airway epithelial remodeling in chronic inflammatory airway diseases including cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease. It disrupts mucociliary clearance, which fuels disease progression. Effective clearance requires an optimal proportion of multiciliated and secretory cells. This is controlled by Notch signaling such that between two adjacent cells the one that activates Notch becomes a secretory cell and the one that avoids Notch activation becomes a multiciliated cell. Consequently, blocking Notch by a small molecule inhibitor of the γ-secretase enzyme that cleaves the Notch receptor for signal activation directs differentiation toward the multiciliated lineage. Thus, γ-secretase inhibitor (GSI) treatment may alleviate multiciliated cell loss in lung disease. Here, we demonstrate the therapeutic restoration of multiciliated cells by the GSI LY450139 (semagacestat). LY450139 increased multiciliated cell numbers in a dose-dependent manner in healthy primary human nasal epithelial cells (HNECs) during differentiation and in mature cultures, but not when applied during early epithelialization of progenitors. LY450139 did not impact stem cell proliferation. Basal and apical administration were equally effective. In healthy adult mice, LY450139 increased multiciliated cell numbers without detectible toxicity. LY450139 also increased multiciliated cells and decreased excess mucus secretory cells in CF HNECs and IL-13 remodeled healthy HNECs. LY450139 normalized multiciliated cell numbers in CF HNECs without interfering with the activity of CFTR modulator compounds. In summary, we demonstrate that GSI administration is a promising therapeutic to restore multiciliated cells and potentially improve epithelial function in a wide range of chronic lung diseases.

Indexed as

AsthmaCystic FibrosisAmyloid Precursor Protein SecretasesAnimalsEpithelial CellsEpitheliumHumansMiceReceptors, NotchSignal TransductionAmyloid Precursor Protein SecretasesReceptors, Notchairway epitheliumciliacystic fibrosisNotchγ-secretase inhibitor

Identifiers

PMID37039381
PMCPMC10202488
OpenAlexW4364353728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.